A noncanonical AR addiction drives enzalutamide resistance in prostate cancer

Yundong He; Ting Wei; Zhenqing Ye; Jacob J. Orme; Dong Lin; Haoyue Sheng; Ladan Fazli; R. Jeffrey Karnes; Rafael Jimenez; Liguo Wang; Liewei Wang; Martin E. Gleave; Yuzhuo Wang; Lei Shi; Haojie Huang

doi:10.1038/s41467-021-21860-7

Nature Communications (Mar 2021)

A noncanonical AR addiction drives enzalutamide resistance in prostate cancer

Yundong He,
Ting Wei,
Zhenqing Ye,
Jacob J. Orme,
Dong Lin,
Haoyue Sheng,
Ladan Fazli,
R. Jeffrey Karnes,
Rafael Jimenez,
Liguo Wang,
Liewei Wang,
Martin E. Gleave,
Yuzhuo Wang,
Lei Shi,
Haojie Huang

Affiliations

Yundong He: Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Science
Ting Wei: Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine and Science
Zhenqing Ye: Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine and Science
Jacob J. Orme: Division of Medical Oncology, Department of Internal Medicine, Mayo Clinic College of Medicine and Science
Dong Lin: Department of Experimental Therapeutics, BC Cancer Research Centre
Haoyue Sheng: Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Science
Ladan Fazli: Department of Experimental Therapeutics, BC Cancer Research Centre
R. Jeffrey Karnes: Department of Urology, Mayo Clinic College of Medicine and Science
Rafael Jimenez: Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine and Science
Liguo Wang: Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine and Science
Liewei Wang: Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine and Science
Martin E. Gleave: The Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia
Yuzhuo Wang: Department of Experimental Therapeutics, BC Cancer Research Centre
Lei Shi: Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Science
Haojie Huang: Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Science

DOI: https://doi.org/10.1038/s41467-021-21860-7
Journal volume & issue: Vol. 12, no. 1
pp. 1 – 14

Abstract

Read online

Resistance to second generation anti-androgen therapies such as enzalutamide (ENZ) can emerge in prostate cancer patients. Here, the authors identify an ENZ-resistant mechanism driven by AR-dependent transcription of noncanonical targets that make resistant cells susceptible to dual inhibition of BET and CBP/p300 signaling.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal